No evidence of survival benefit with addition of gemtuzumab ozogamicin to standard medical research council induction chemotherapy.

Jensen, Morten Krogh

Jensen, Morten Krogh.

J Clin Oncol ; 31(13): 1700, 2013 May 01.

Article in En | MEDLINE | ID: mdl-23530103

Subject(s)

Aminoglycosides/therapeutic use; Antibodies, Monoclonal, Humanized/therapeutic use; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Leukemia, Myeloid, Acute/drug therapy; Leukemia, Myeloid, Acute/mortality; Myelodysplastic Syndromes/drug therapy; Myelodysplastic Syndromes/mortality; Female; Humans; Male

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Myelodysplastic Syndromes / Leukemia, Myeloid, Acute / Antineoplastic Combined Chemotherapy Protocols / Antibodies, Monoclonal, Humanized / Aminoglycosides Limits: Female / Humans / Male Language: En Journal: J Clin Oncol Year: 2013 Document type: Article

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google